Lisata Therapeutics, INC 8-K filings

Lisata Therapeutics announced a 72% workforce reduction, estimated $1.2 million in costs, and initiated legal action against Kuva Labs for breach of a merger agreement.

Lisata Therapeutics has terminated its merger agreement with Kuva Labs Inc. due to financing issues, triggering a $2 million termination fee and prompting a strategic review.

Lisata Therapeutics, Inc. and Kuva Labs Inc. have amended their merger agreement, extending the outside date to July 21, 2026.

Lisata Therapeutics and Kuva Labs Inc. have amended their merger agreement, extending key deadlines and outlining payment terms for delayed actions.

Lisata Therapeutics announced a delay in the commencement of its tender offer for common stock, citing ongoing negotiations with financing sources.

Lisata Therapeutics has amended its merger agreement with Kuva Labs, reducing the upfront cash payment to $4.00 per share while increasing the potential value of contingent value rights (CVRs) to $3.00.

Lisata Therapeutics and Kuva Labs Inc. have amended their merger agreement, extending the tender offer commencement date and outlining interim operating payments.

Lisata Therapeutics announced an extension of the tender offer deadline due to the acquirer seeking more favorable financing terms, with no assurance on commencement timing.

Lisata Therapeutics and Kuva Labs Inc. have extended the expiration date of their binding term sheet for a proposed acquisition until March 7, 2026.

Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. have mutually terminated their exclusive license and collaboration agreement for certepetide in Greater China.

Lisata Therapeutics has entered a binding term sheet to be acquired by Kuva Labs for $4.00 per share in cash, plus two contingent value rights each worth $1.00.

Lisata Therapeutics announced positive clinical data from multiple certepetide trials, strategic partnerships, and extended its cash runway into Q1 2027, alongside a decrease in operating expenses for Q3 2025.

Lisata Therapeutics, Inc. announced its corporate presentation highlighting the advancement of its lead product candidate, certepetide, to a global Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, supported by positive Phase 2b data and a strong financial position.

Lisata Therapeutics entered a non-exclusive license agreement with Catalent, Inc. for its certepetide in antibody drug conjugates, potentially yielding up to $10.5 million in milestones and future revenue sharing.

Lisata Therapeutics announced positive clinical data for certepetide in solid tumors, extended its cash runway into Q4 2026, and reported reduced net losses for the second quarter of 2025.

Lisata Therapeutics announced the issuance of a new U.S. composition of matter patent for its investigational drug certepetide, providing exclusive rights and extending intellectual property protection until March 2040.

Lisata Therapeutics announced promising preliminary Cohort B data from its Phase 2b ASCEND trial, showing improved progression-free survival and objective response rates for certepetide in metastatic pancreatic cancer, paving the way for a global Phase 3 study.

Lisata Therapeutics announced an extension of its cash runway into the fourth quarter of 2026, alongside significant clinical progress for its lead asset, Certepetide, including an agreed-upon Phase 3 study design with the FDA for metastatic pancreatic ductal adenocarcinoma.

Lisata Therapeutics Inc. has amended employment and separation benefits agreements for its key executives, including salary increases for the CEO and CMO, and clarified severance terms, particularly in Change in Control scenarios.

Lisata Therapeutics, Inc. announced that its stockholders approved all five proposals at the 2025 Annual Meeting, including the re-election of two Class III directors and an increase in shares for the Employee Stock Purchase Plan.

Lisata Therapeutics announced its Q1 2025 financial results and provided a business update, highlighting encouraging clinical trial data and a cash runway extending into the third quarter of 2026.

Lisata Therapeutics highlights promising preliminary Phase 2b pancreatic cancer data, completes enrollment in a Qilu Phase 2 trial, advances its development portfolio, and extends its cash runway into the second quarter of 2026.

Lisata Therapeutics reports encouraging preliminary data from Cohort A of the Phase 2 ASCEND trial, showing a positive trend in overall survival for certepetide in combination with standard chemotherapy for metastatic pancreatic cancer.

Lisata Therapeutics has granted Kuva Labs an exclusive worldwide license for the development and commercialization of certepetide, a novel cyclic peptide.

Lisata Therapeutics announced its third quarter 2024 financial results and provided a business update, highlighting progress in its development portfolio and upcoming data readouts.

Lisata Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and reaffirming its cash runway into early 2026.

Lisata Therapeutics stockholders approved the re-election of three directors, amendments to equity incentive plans, an increase in shares for the employee stock purchase plan, and ratified the appointment of Grant Thornton LLP as the company's auditor at the 2024 Annual Meeting.

Lisata Therapeutics announced its first quarter 2024 financial results, highlighted by a strong start to a pivotal year with key clinical trial data expected, and reaffirmed its cash runway into early 2026.

Lisata Therapeutics has appointed James Nisco as its new Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective April 15, 2024.

Lisata Therapeutics reports its full year 2023 financial results, highlighting the completion of enrollment in the Phase 2b ASCEND trial and reaffirming its operational funding projection into early 2026.